UBS analyst Ashwani Verma lowered the firm’s price target on Legend Biotech (LEGN) to $48 from $54 and keeps a Buy rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech highlights new CARVYKTI data in RRMM
- H.C. Wainwright says Legend Biotech competition concerns overdone
- Buy Rating for Legend Biotech Reaffirmed Due to CARVYKTI’s Strong Market Position and Proven Efficacy
- Legend Biotech price target raised to $75 from $66 at Cantor Fitzgerald
- Legend Biotech price target lowered to $90 from $94 at Barclays